×

PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")

REGULATED INFORMATION

GHENT, Belgium, Nov. 25, 2013 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX], today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received a notification of shareholdings from Biotech Value Fund Partners LP (BVF Partners LP), Biotech Value Fund Inc (BVF Inc) and Sofinnova Partners SAS.

Biotech Value Fund Partners LP and Biotech Value Fund Inc notified that they have exceeded the 5% threshold and now hold 2,554,524 Ablynx shares, which represent 5.23% (compared to a 3.49% holding at 30 September 2013) of the current 48,827,645 outstanding shares of Ablynx.

Sofinnova Partners SAS notified that they have dropped below the 3% threshold and now have sold their complete stake in Ablynx.

As the general partner of Biotechnology Value Fund LP (BVF) and Biotech Value Fund II LP (BVF 2), BVF Partners LP (Partners) is authorised to exercise the voting rights owned directly by BVF and BVF 2. As the advisor to Investment 10, LLC (INV 10) and the manager of BVF Investments, LLC (BVF LLC) BVF Partners is authorised to exercise the voting rights owned directly by INV10 and BVF LLC. As the general partner of BVF Partners, BVF Inc has management authority over BFV Partners. As the President of BFV Inc, Mr Lampert has management authority over BFV Inc.

Full versions of all transparency notifications are available on the website of Ablynx, under the section Investors.

About Ablynx

Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, haematology, oncology and pulmonary disease. Today, the Company has approximately 30 programmes in the pipeline and seven Nanobodies at clinical development stage. Ablynx has on-going research collaborations and significant partnerships with major pharmaceutical companies including AbbVie, Boehringer Ingelheim, Eddingpharm, Merck & Co, Merck Serono and Novartis. The Company is headquartered in Ghent, Belgium.

More information can be found on www.ablynx.com.

pdf version of the press release: http://hugin.info/137912/R/1745629/587503.pdf

CONTACT: For more information, please contact Ablynx: Dr Edwin Moses CEO t: +32 (0)9 262 00 07 m: +44 (0)7771 954 193 / +32 (0)473 39 50 68 e: edwin.moses@ablynx.com Marieke Vermeersch Associate Director Investor Relations t: +32 (0)9 262 00 82 m: +32 (0)479 49 06 03 e: marieke.vermeersch@ablynx.com Follow us on Twitter @AblynxABLX Ablynx media relations Consilium Strategic Communications: Mary-Jane Elliott, Amber Bielecka, Lindsey Neville t: +44 207 920 2345 e: ablynx@consilium-comms.comSource:Ablynx